Products

What will AGI do for Bizelesin?

This classification denotes an antineoplastic alkylating agent with the molecular formula C43H36Cl2N8O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0O9OBI87E, chemically known as 1,3-bis(2-(((s)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo(1,2-b:4,3-b)dipyrrol-3(2h)-yl)carbonyl)indol-5-yl)urea but more generally known as bizelesin, which bears US NIH Compound Identifier 60794. European Medicines Agency schedules Bizelesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05863MIG. The term BIZELESIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). BIZELESIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule bizelesin under HS 29339990 and SITC 51577. As of Q4 2014, BIZELESIN remains US FDA's Preferred Term for this commodity. Bizelesin bears US NLM identifiers UMLS ID C0209891 and NCI Concept Code C1472. SMILES: CLCC1C2C(N(C1)C(=O)C1[NH]C3C(C1)CC(NC(=O)NC1CC4CC([NH]C4CC1)C(=O)N1CC(C4C1CC(O)C1[NH]CC(C41)C)CCL)CC3)CC(O)C1[NH]CC(C21)C.